1st Apr 2011 12:00
Annual Information Update
April 1, 2011 - Shire plc , the global specialty biopharmaceutical company, announces its Annual Information Update in accordance with the requirements of Prospectus Rule 5.2. This is in relation to information that has been published or made available to the public between April 1, 2010 and March 31, 2011.
The information referred to in this Annual Information Update was correct at the time the information was published, but some information may now be out of date. The information appears by way of record and the Company is under no obligation to update it.
1. Announcements made via a RIS
The documents listed below were published via a Regulatory Information Service on or around the dates indicated.
29-Mar-11 Holding(s) in Company 24-Mar-11 2010 Annual Report - DTR 6.3.5 Disclosure 21-Mar-11 FDA Assigns PDUFA Date for Shire's FIRAZYR® 03-Mar-11 EC Approves Self-Administration Label for FIRAZYR® 02-Mar-11 Correction : Director/PDMR Shareholding 01-Mar-11 Director/PDMR Shareholding 01-Mar-11 Total Voting Rights 01-Mar-11 Elections for Second Interim Dividend 28-Feb-11 Shire Files Complete Response to FDA 24-Feb-11 Shire Receives new Paragraph IV Notice Letter 10-Feb-11 Outstanding 2010 results: Non GAAP EPS up 21% to $4.23. Good earnings growth expected in 2011. 01-Feb-11 Total Voting Rights 31-Jan-11 Full Year 2010 results date notification 10-Jan-11 Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules CII in Excessive Daytime Sleepiness Model 04-Jan-11 Total voting rights 03-Dec-10 INTUNIV - Shire Files Suit against Impax and Watson 01-Dec-10 Total Voting Rights 01-Dec-10 Positive Results From FAST-3 Study of FIRAZYR(R) 23-Nov-10 Blocklisting - Interim Review 10-Nov-10 Five-Year Market Exclusivity for VYVANSE® Upheld 09-Nov-10 Shire finalises its acquisition of Movetis NV 02-Nov-10 Director/PDMR Shareholding 01-Nov-10 Total Voting Rights 01-Nov-10 Shire Receives INTUNIV(TM) Paragraph IV Notice Letter 29-Oct-10 Continued excellent performance in Q3 29-Oct-10 VYVANSE(R) - Shire Reports Positive Signal Finding Study 26-Oct-10 Shire Receives INTUNIV(TM) Paragraph IV Notice Letter 18-Oct-10 Third quarter 2010 results date notification 13-Oct-10 Shire Acquires 99.21% of the shares of Movetis N.V. 01-Oct-10 Total Voting Rights 30-Sep-10 Results of the Tender Offer for Movetis NV 09-Sep-10 Shire Expands Pipeline to Treat Orphan Muscle Diseases 06-Sep-10 Re Acquisition 01-Sep-10 Total Voting Rights 01-Sep-10 Elections for Interim Dividend 26-Aug-10 Shire Announces European Approval of VPRIV# 26-Aug-10 Notification of major interests in shares 24-Aug-10 Pentasa - Shire Receives Ruling From FDA 20-Aug-10 Correction - Director/PDMR Shareholding 20-Aug-10 Director/PDMR Shareholding 17-Aug-10 Director/PDMR Shareholding 11-Aug-10 Half Yearly Report - Part 1 11-Aug-10 Half Yearly Report - Part 3 11-Aug-10 Half Yearly Report - Part 2 11-Aug-10 Half Yearly Report - Part 4 11-Aug-10 Shire agrees to divest Daytrana(R) to Noven 05-Aug-10 Director/PDMR Shareholding 04-Aug-10 Shire delivers excellent Q2 performance - Part 3 04-Aug-10 Shire delivers excellent Q2 performance - Part 2 04-Aug-10 Shire delivers excellent Q2 performance - Part 1 03-Aug-10 Shire Proposes to Expand Specialist GI Portfolio 02-Aug-10 Total Voting Rights 15-Jul-10 Second quarter 2010 results date notification 08-Jul-10 Lialda - Shire Files Suit against Zydus 01-Jul-10 Total Voting Rights 30-Jun-10 Shire Purchases Strategic Site in Massachusetts 25-Jun-10 Shire Receives CHMP Positive Opinion for VPRIV 21-Jun-10 Director/PDMR Shareholding 17-Jun-10 Directorate Change 03-Jun-10 Shire Files Suit against Anchen 01-Jun-10 Total Voting Rights 01-Jun-10 Shire Receives Paragraph IV Notice Letter 24-May-10 Blocklisting - Interim Review 13-May-10 INTUNIV[TM] - Shire Files Suit against Actavis 04-May-10 Total Voting Rights 29-Apr-10 1st Quarter Results 27-Apr-10 Shire Receives INTUNIV(TM) Paragraph IV Notice Letter 27-Apr-10 Result of AGM 23-Apr-10 INTUNIV - Shire Files Suit against Teva 20-Apr-10 1st qtr. 2010 results date notification - April 29, 2010 06-Apr-10 Shire Receives 2nd INTUNIV Paragraph IV Notice Letter 01-Apr-10 Total Voting Rights 01-Apr-10 Annual Information Update 01-Apr-10 Director/PDMR Shareholding
2. Documents filed with the Securities and Exchange Commission ("SEC")
The Company submitted filings to the SEC in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having American Depository Shares admitted to trading on the NASDAQ. Full details of these filings can be found on the SEC's website at www.sec.gov.
3. Documents filed with Companies Registry, Jersey
Date of Delivery Document
21-Feb-11 Annual Return
06-May-10 Special Resolution passed on April 27, 2010
26-Apr-10 Annual Report and Accounts for the year ended December 31, 2009
4. Documents sent to Shareholders
The following documents were published and sent to shareholders, and are available on the Company's website.
Date of Delivery Document
24-Mar-11 Annual Report and Accounts for the year ended December 31, 2010
24-Mar-11 Notice of 2011 Annual General Meeting
A copy of this Annual Information Update and copies of the documents referred to in it can be obtained from the Deputy Company Secretary at the Company's registered office.
Tony GuthrieDeputy Company Secretary
For further information please contact:
Investor Relations Eric Rojas [email protected] +1 781 482 0999 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PXPress Release
www.shire.com
vendorRelated Shares:
Shire